{
event: "article_read",
name: `Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE) `,
author: ``,
tags: `Thrombosis`,
publication_date: ``,
interaction_type: "content"
}
Specific Patient Characteristics Linked to Below Average Quality of Life in Patients with Recent Venous Thromboembolism (VTE)
Many associated factors are modifiable indicating potential benefit from planned strategies.
Key Takeaway
Specific, definable patient characteristics are associated with below average quality of life (QoL) in patients with recent venous thromboembolism (VTE).
The most notable factors associated with below average QoL were current depression and/or anxiety, unemployment, African American race, anticoagulant-related bleeding and difficulty getting VTE care.
Importantly, factors associated with physical and mental QoL were different.
Why This Matters
Patients with VTE have been known to have deficits in QoL.
However, understanding regarding drivers of poorer QoL in patients with VTE is limited.
Potential strategies to address poor QoL in such patients could include increased counselling, patient-support network referral, better access to credible educational materials, transportation solutions for medical appointments, programmes to address affordability of anticoagulant medications and resources to assist with anxiety and depression.
Study Design
Study evaluated data from a cross-sectional national online survey of 907 adult patients (mean age, 52.4 years) who experienced at least one self-reported VTE episode within the past 2 years.
The survey contained a variety of questions designed to ascertain QoL scores and potential factors associated with QoL.
QoL score was collected using the Optum Health Survey Short Form-12 (SF-12).
SF-12 comprised of Physical Health Component Summary (PCS) and Mental Health Component Summary (MCS) scores.
Funding: Pfizer Independent Grants for Learning & Change, Bristol-Myers Squibb Independent Medical Education and The Joint Commission.
Key Results
Mean PCS and MCS scores were 41.7 (standard deviation [SD], 10.2) and 46.7 (SD, 10.9), respectively with majority of patients having below average PCS (76.0%) and MCS (56.7%) scores.
Factors associated with below average PCS were:
high depression scores (aOR, 4.02; 95% CI, 1.88-2.54);
being unemployed (aOR, 3.77; 95% CI, 1.76-8.05);
African American race (aOR, 6.54; 95% CI, 1.01-42.27);
reporting blood in the stool (aOR, 2.54; 95% CI, 1.28-5.01);
worry about clotting (aOR, 1.60; 95% CI, 1.04-2.48) and
difficulty getting VTE care (aOR, 4.24; 95% CI, 1.77-10.17).
Factors associated with below MCS scores were:
high depression scores (aOR, 3.85; 95% CI, 1.6-9.28);
being unemployed (aOR, 2.83; 95% CI 1.30-6.16);
experiencing VTE within the past month (aOR, 3.85; 95% CI, 1.58-9.41);
switching between direct oral anticoagulants (aOR, 4.24; 95% CI, 1.00-17.93) and
high anxiety score (aOR, 9.17; 95% CI, 4.81-17.47).
Experiencing more lifetime VTE episodes (aOR, 0.94; 95% CI, 0.89-0.99) and older age (aOR, 0.97; 95% CI, 0.95-0.99) were associated with above average PCS and MCS scores, respectively.
Limitations
Less than ideal response rate.
Index VTE identification was self-reported.
All variables potentially affecting QoL were not collected.
Certain events may have been over- or under-reported due to patient recall bias.
Erickson RM, Feehan M, Munger MA, Tak C, Witt DM. Understanding Factors Associated with Quality of Life in Patients with Venous Thromboembolism. Thromb Haemost. 2019;119(11):1869-1876. doi: 10.1055/s-0039-1696717. PMID: 31587248
Related articles
Thrombosis
Changing trends in VTE: Pulmonary Embolism cases on Rise within the Last Decade
Danish study finds more elderly and patients with comorbidities being diagnosed.
Evaluation Of Comparative Efficacy and Safety of Thromboprophylaxis Agents Among Critically Ill Patients
This systematic review and network meta-analysis revealed that the use of low-molecular-weight heparin (LMWH) may be more effective than unfractionated heparin (UFH) in reducing incidence of deep vein thrombosis (DVT) among critically ill patients.
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.